BRIGHTSPRING HEALTH SERVICES INC (BTSG)
Sector: Health Care
2026 Annual Meeting Analysis
BRIGHTSPRING HEALTH SERVICES INC · Meeting: May 21, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Ms. Kirtley joined the board in 2024 (well within the 24-month new-director exemption from the TSR trigger), brings deep audit, financial reporting, and governance expertise including CPA credentials and prior public company board experience, and serves as an independent Audit Committee Chair with no overboarding or attendance concerns.
Mr. Lin has served since 2017 and represents the KKR Stockholder; the TSR trigger does not apply because BrightSpring's 3-year price return of +312.1% outperforms the company-disclosed peer group median of +34.6% by +277.5 percentage points, far above the 65-point threshold required to trigger a vote against at this level of absolute positive TSR; his current board seat count across public companies does not appear to breach the overboarding threshold based on disclosed information.
Dr. Miller joined the board in 2024 (within the 24-month new-director exemption), brings relevant clinical and business expertise in healthcare through senior roles at Cigna and Express Scripts, and serves as an independent director with no attendance or overboarding concerns identified.
All three Class II director nominees — Olivia Kirtley, Max Lin, and Steve Miller — receive a FOR vote. BrightSpring's 3-year total shareholder return of +312.1% massively outperforms the company-disclosed peer group median of +34.6%, so the TSR underperformance trigger does not fire for any director. Two of the three nominees (Kirtley and Miller) joined in 2024 and are independently exempt as new directors. No overboarding, attendance, independence, or qualification concerns are identified.
Say on Pay
✓ FORCEO
Jon Rousseau
Total Comp
$17,841,460
Prior Support
N/A
CEO Jon Rousseau's total reported compensation of $17.8 million is within a reasonable range for a CEO of a large-cap healthcare services company with $8.7 billion market cap and $12.9 billion in revenue, and the pay structure is heavily weighted toward variable pay (salary of $1.3 million represents roughly 7% of total compensation, well below the 40% fixed-pay flag threshold). The annual cash incentive plan uses measurable financial targets (EBITDA and revenue) with a minimum gate that must be satisfied before any payout, and above-target payouts in 2025 reflect genuine outperformance — Adjusted EBITDA came in at $760 million versus a target of $661 million (115% achievement). Pay-for-performance alignment is strong: the company's 3-year stock price return of +312.1% far exceeds the disclosed peer group median of +34.6%, meaning shareholders have been well rewarded during the same period executives received above-target incentive compensation; the company also discloses a clawback policy compliant with SEC and Nasdaq requirements.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$4,532,000
Non-Audit Fees
$707,305
Non-audit fees (audit-related fees of $530,000 plus tax fees of $166,245 plus other fees of $11,060, totaling $707,305) represent approximately 15.6% of core audit fees of $4,532,000, well below the 50% threshold that would raise independence concerns; KPMG is a Big 4 firm appropriate for a company of BrightSpring's size; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire per policy; no material restatements are disclosed.
Overall Assessment
BrightSpring's 2026 annual meeting presents a clean ballot with no significant governance concerns: all three Class II director nominees are well-qualified and the company's exceptional stock performance means the TSR underperformance trigger does not apply to any director; the executive compensation program is heavily performance-based with demonstrable pay-for-performance alignment, and KPMG's non-audit fee ratio is well within acceptable bounds. All three proposals receive a FOR vote.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing